Business
Programme and technical development update
Aptamer Group plc has reported significant progress across its strategic initiatives, including the delivery of its first AI-generated Optimer® candidates for laboratory testing, demonstrating the rapid development of its AI platform which has been trained on 450,000 sequences. The company has also invested in automation equipment to enhance discovery capabilities and is advancing its therapeutic pipeline, with radioligand therapy programmes nearing first in vivo data by the end of 2026, achieving over 99% radiochemical purity in radiolabelling. Furthermore, Aptamer has identified promising kidney-targeting siRNA delivery vehicles with excellent selectivity, adding to its versatile delivery vehicle portfolio. Disclaimer*
About this update from Aptamer Group Plc
25 June 2026 Aptamer Group plc ("Aptamer", the "Company" or the "Group") Programme and technical development update First AI-generated Optimer® candidates delivered for laboratory testing Discovery and manufacturing capabilities expanded through automation investment Radioligand therapy programme advances towards first in vivo data Kidney-targeting siRNA delivery vehicles identified with promising selectivity profile Aptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce an update on the delivery of strategic initiatives across its platform technology and therapeutic development programmes, supported by the April 2026 fundraise. The Group is making simultaneous progress across its AI platform, platform automation, and therapeutic pipeline, demonstrating strong operational momentum across multiple pillars of the business. AI development programme Aptamer has initiated its AI development programme, representing a significant step towards building an AI-enabled Optimer® discovery engine. As set out at the time of the fundraise, the Group is targeting the use of AI to accelerate and enhance the discovery of Optimer® binders against challenging targets, aiming to deliver faster, improved services, with insights into undruggable proteins, such as transcription factors and RNA-binding proteins. Following the appointment of a senior machine learning expert in April 2026, the team has progressed rapidly. The AI model architecture has been built and trained on a preliminary in-house dataset of 450,000 sequences spanning 42 protein targets; a significantly broader target range than most published AI models. Aptamer's current model has already demonstrated the ability to screen candidates, speeding up the selection process. Initial Optimer® candidates have been identified from the AI model and are being manufactured for laboratory testing. With over half of Aptamer's in-house dataset yet to be integrated into the model, the Group anticipates further improvements in accuracy and predictive power across a wider range of targets as training continues. Platform automation In line with the Group's fundraising objectives, capital expenditure has been deployed to purchase new automation equipment, enhancing Apt...